Address correspondence to Dr Sarah E. Nelson, Johns Hopkins University, 600 N Wolfe St, Phipps 455, Baltimore, MD 21287, firstname.lastname@example.org.
RELATIONSHIP DISCLOSURE: Dr Nelson receives grant support from the Johns Hopkins Anesthesiology and Critical Care Medicine (ACCM) Stimulating and Advancing ACCM Research (StAAR) program. Dr Varelas serves on the board of directors of the Neurocritical Care Society, on the editorial board of Neurocritical Care, and on an advisory board of Portola Pharmaceuticals, Inc. Dr Varelas has received personal compensation for speaking engagements for Portola Pharmaceuticals, Inc and UCB SA and receives publishing royalties from Springer. Dr Varelas receives research/grant support from Bard Pharmaceuticals Limited; Edge Therapeutics, Inc; Marinus Pharmaceuticals, Inc; the National Institutes of Health; the Patient-Centered Outcomes Research Institute; and Portola Pharmaceuticals, Inc.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Nelson and Varelas discuss the unlabeled/investigational use of allopregnanolone, deep brain stimulation, desflurane, diazepam, electroconvulsive therapy, fosphenytoin, gabapentin, isoflurane, IV immunoglobulin, ketamine, ketogenic diet, lacosamide, levetiracetam, lidocaine, lorazepam, methylprednisolone, midazolam, pentobarbital, phenobarbital, phenytoin, plasma exchange, propofol, pyridoxine, thiopental, topiramate, vagal nerve stimulation, and valproic acid for the treatment of refractory status epilepticus.
CONTINUUM AUDIO INTERVIEW AVAILABLE ONLINE